Cellectar Biosciences, Inc.
Cellectar Biosciences, Inc. (Nasdaq: CLRB) is a clinical-stage biopharmaceutical company developing cancer treatments using its phospholipid drug conjugate (PDC) delivery platform. The platform is designed to target cancer cells and deliver therapeutic payloads, including radioisotopes, while limiting exposure to… From the company’s description.
In fiscal 2025, Cellectar Biosciences, Inc. reported a net loss of $21.79M. Operations used $23.12M in cash.
Margins and return on equity change in ; everything else in percent. Fewer shares and less debt are shown plainly, not as bad news — it depends what you make of buybacks. Dotted labels explain each measure. is shown separately from the annual figures.
What Cellectar Biosciences, Inc. does
In the company’s own words
Cellectar Biosciences, Inc. (Nasdaq: CLRB) is a clinical-stage biopharmaceutical company developing cancer treatments using its phospholipid drug conjugate (PDC) delivery platform. The platform is designed to target cancer cells and deliver therapeutic payloads, including radioisotopes, while limiting exposure to healthy tissue. Its lead programs are iopofosine I 131, a beta-emitting radioconjugate studied in blood cancers and pediatric and solid tumors; CLR 125, an iodine-125 Auger-emitting candidate being evaluated in advanced triple-negative breast cancer; and CLR 225, an actinium-225 alpha-emitting candidate in preclinical development for solid tumors. The company also develops PDCs with small-molecule, peptide and nucleic-acid payloads and pursues research collaborations to advance its platform and pipeline. Its clinical programs address multiple myeloma, Waldenstrom macroglobulinemia, central nervous system lymphoma, pediatric cancers and recurrent head and neck cancer. Cellectar’s CLOVER studies evaluate iopofosine across hematologic malignancies and pediatric cancers; its CLOVER WaM study focuses on relapsed or refractory Waldenstrom macroglobulinemia.
Company details
- Sector
- Health Care
- Industry (SIC)
- Pharmaceutical Preparations
- Headquarters
- FLORHAM PARK, NJ
- Fiscal year end
- December
- CIK
- 1279704
- SIC
- 2834
Financial performance, year by year
Fiscal 2011–2025 · USDThe full income statement, balance sheet and cash flow for each of these years — every figure traceable to its filing — is on the Financials tab with a free account.
Who owns Cellectar Biosciences, Inc. — and what changed
Funds as of 2026Q2 · superinvestors as of 2026-06-30
Largest fund holders · Cellectar Biosciences, Inc.’s weight in each
Fund ownership is a floor, not a census — pensions, insurers and people holding shares directly are not visible here.
Fund ownership counts N-PORT filers only, so it is a floor rather than a census — pensions, insurers and direct holders are not visible here, and the remainder is not “held by individuals”.
Every fund and institutional holder, quarter by quarter, is on the Ownership tab with a free account.
Recent filings
All filings →Each filing opens into its own statements and disclosures here.
Put this business in context.
Compare this company with peers, find it in your funds and follow its financial history with your connected AI:
- “How do Cellectar Biosciences, Inc. and its peers compare on margins and cash generation over ten years?”
- “Where did five years of Cellectar Biosciences, Inc.'s earnings go — cash, debt, buybacks, reinvestment?”
- “What changed in Cellectar Biosciences, Inc.'s last four quarterly filings that the numbers alone won't show?”